Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L  + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results

CONCLUSIONS: With longer-term survival data, axi-cel continues to represent a cost-effective option versus tisa-cel for treatment of r/r LBCL among patients who have previously received ≥2 lines of systemic therapy, from a US payer perspective.PMID:38240256 | DOI:10.1080/13696998.2024.2305558

Source: Journal of Medical Economics - January 19, 2024 Category: Health Management Authors: Olalekan O Oluwole Markqayne D Ray Neil Davies Rory Bradford Calum Jones Anik R Patel Frederick L Locke Source Type: research